text:
Are you Yan Ren?Claim your profile
Publications (8)16.69 Total impact
Article: Analysis of mouse liver membrane proteins using multidimensional ion exchange chromatography and tandem mass spectrometry[Show abstract] [Hide abstract]
ABSTRACT: The analysis of membrane proteins is still a technical obstacle in proteomic investigation. A fundamental question is how to allow the hydrophobic proteins fully solubilizing in a proper solvent environment. We propose that the denatured membrane proteins in high denaturant solution are fully ionized and separated through ion exchange chromatography. The membrane proteins prepared from a mouse liver were dissolved in 4 mol/L urea, 20 mmol/L Tris-HCl buffer (pH 9.0), and loaded onto a tandem chromatography coupled with Q-Sepharose FF and Sephacryl S-200HR. With a linear NaCl gradient elution, the bound proteins were eluted and collected followed by sodium-dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) to further separate the eluted proteins. The protein bound on SDS-PAGE were excised and in-gel digested by trypsin, while the digested peptides were delivered to reversed-phase high performance liquid chromatography (HPLC) and ion-trap mass spectrometry for the peptide identifications. Of a total of 392 proteins identified, 306 were membrane proteins or membrane associated proteins reported by literature. Based on the calculation of hydrophobicity, the GRAVY (grand average of hydropathicity) scores of 83 proteins are over or equal to 0.00. Taking all the evidence, we have established an effective approach which is feasible in the investigation towards mouse liver membrane proteomics.
- [Show abstract] [Hide abstract]
ABSTRACT: The aldo-keto reductase (AKR) proteins catalyze reduction of diverse aldehydes and play detoxification roles in many organisms. Since many substrates are shared among AKR, it is generally accepted that these enzymes can functionally compensate each other in response to oxidative stress. Their overall abundances are the important factor that partially reflects the capacity of antioxidant and detoxification in tissues. In this study, the strategy was proposed for generation of Pan-AKR antibodies to recognize most AKR proteins in mouse tissues. Derived from bioinformatic analysis, several consensus peptides with different potential antigenicities were synthesized, conjugated to hemocyanin from keyhole limpets and further delivered to rabbits to generate polyclonal antibodies. Three Pan-AKR antibodies exhibited the immune specificities and immune sensitivities, Pan-AKR-P1 for AKR1B and AKR1C, Pan-AKR-P3 for AKR1C and Pan-AKR-P4 for all the AKR proteins. Pan-AKR-P4 antibody was employed to 2-DE Western blot to examine the AKR abundances in mouse liver and kidney, resulting in seven immune-reactive spots from each tissue. Protein identification with MS revealed that most immune-positive spots were the members of AKR superfamily. Furthermore, Pan-AKR-P4 antibody was implemented to compare the different abundances of the AKR proteins in liver and kidney between normal and diabetic mice, suggesting that diabetes did cause some abnormal changes in the AKR protein abundances.
- [Show abstract] [Hide abstract]
ABSTRACT: A fundamental issue for sepsis therapy is to control the development of inflammation at an early stage. With cecal ligation and puncture (CLP) surgery, the mouse model has clearly shown the septic signs triggered by chronic insult. To monitor the plasma proteomic responses to sepsis, the mouse blood was collected at intervals after sham and CLP surgery followed by the sample treatment to remove high abundance serum albumin. The treated mouse plasma proteins were well resolved by two-dimensional electrophoresis (2-DE). The image analysis revealed that these 2-DE spots observed from the sham and the CLP samples 4 h after surgery were comparable, whereas more than 30 different spots appeared on the 2-DE gels between the sham and CLP mouse plasma 24 h after surgery, indicating that some plasma proteins responded to the inflammatory development. These differential spots were verified by MALDI-TOF/TOF MS, resulting in 13 unique sepsis-responsive proteins. More importantly, most of them exhibited multiple spots as difference on the 2-DE gels. Furthermore, these isospots were incubated with PNGase F to eliminate N-linked oligosaccharides on proteins and then evaluated by Western blot as well as mass spectrometry. The results of PNGase F digestion suggested that most sepsis-associated proteins remained in N-glycosylation status but changed their N-glycans during septic development.
Article: Seeking Transformation Markers: An Analysis of Differential Tissue Proteomes on the Rice Germplasm Generated from Transformation of Echinochloa crusgalli Genomic DNA[Show abstract] [Hide abstract]
ABSTRACT: The transformation of distally related genomic DNAs into plant was proposed as a novel technique to breed new cultivars. For example, a restorer rice line, RB207, was successfully developed and stabilized through the transformation of genomic DNAs of Echinochloa crusgalli (E. crusgalli) into a rice line, R207. Although the phenotypes of this variant line are apparently different from its receptor, the molecular bases are not elucidated yet. Herein, we have systematically studied the differential proteomes from the tissues of E. crusgalli, R207, and RB207 in an attempt to find an explanation regarding the phenotypic changes of RB207. The 2-DE method was employed to separate the leaf and embryo proteins of these plants followed by protein identification with mass spectrometry. In the leaf, 953 +/- 15, 1084 +/- 11, and 1091 +/- 11 silver-stained spots were detected, whereas in the embryo, 986 +/- 3, 884 +/- 10, and 892 +/- 14 spots were found from E. crusgalli, R207, and RB207, respectively. In comparison to the 2-DE images of the two rice lines, which showed many similarities, the ones of the E. crusgalli and rice were found to be so different that they were incomparable. There were some differentially expressed 2-DE spots between the two rice cultivars, 72 in leaf and 53 in embryo, respectively. The results of protein identification suggested that, regardless of leaves or embryos, none of the E. crusgalli genes were encoded in the new rice cultivar, RB207. The fact that 60% of the differentially expressed spots between R207 and RB207, however, were verified as the proteins involved in metabolism and photosynthesis makes a rather convincing argument that the DNA fragments transferred from E. crusgalli to rice are responsible for exerting the unknown influence to the expression of rice genes.
- [Show abstract] [Hide abstract]
ABSTRACT: Snake venom is a complex mixture of proteins and peptides, and a number of studies have described the biological properties of several venomous proteins. Nevertheless, a complete proteomic profile of venom from any of the many species of snake is not available. Proteomics now makes it possible to globally identify proteins from a complex mixture. To assess the venom proteomic profiles from Naja naja atra and Agkistrodon halys, snakes common to southern China, we used a combination strategy, which included the following four different approaches: (i) shotgun digestion plus HPLC with ion-trap tandem MS, (ii) one-dimensional SDS/PAGE plus HPLC with tandem MS, (iii) gel filtration plus HPLC with tandem MS and (iv) gel filtration and 2DE (two-dimensional gel electrophoresis) plus MALDI-TOF (matrix-assisted laser desorption ionization-time-of-flight) MS. In the present paper, we report the novel identification of 124 and 74 proteins and peptides in cobra and viper venom respectively. Functional analysis based upon toxin categories reveals that, as expected, cobra venom has a high abundance of cardio- and neurotoxins, whereas viper venom contains a significant amount of haemotoxins and metalloproteinases. Although approx. 80% of gel spots from 2DE displayed high-quality MALDI-TOF-MS spectra, only 50% of these spots were confirmed to be venom proteins, which is more than likely to be a result of incomplete protein databases. Interestingly, these data suggest that post-translational modification may be a significant characteristic of venomous proteins.
- [Show abstract] [Hide abstract]
ABSTRACT: In the face of the worldwide threat of severe acute respiratory syndrome (SARS) to human life, some of the most urgent challenges are to develop fast and accurate analytical methods for early diagnosis of this disease as well as to create a safe anti-viral vaccine for prevention. To these ends, we investigated the antigenicity of the spike protein (S protein), a major structural protein in the SARS-coronavirus (SARS-CoV). Based upon the theoretical analysis for hydrophobicity of the S protein, 18 peptides were synthesized. Using Enzyme-Linked Immunosorbent Assay (ELISA), these peptides were screened in the sera from SARS patients. According to these results, two fragments of the S gene were amplified by PCR and cloned into pET-32a. Both S fragments were expressed in the BL-21 strain and further purified with an affinity chromatography. These recombinant S fragments were confirmed to have positive cross-reactions with SARS sera, either by Western blot or by ELISA. Our results demonstrated that the potential epitope regions were located at Codons 469-882 in the S protein, and one epitope site was located at Codons 599-620. Identification of antigenic regions in the SARS-CoV S protein may be important for the functional studies of this virus or the development of clinical diagnosis.
- [Show abstract] [Hide abstract]
ABSTRACT: The nucleocapsid protein (N protein) has been found to be an antigenic protein in a number of coronaviruses. Whether the N protein in severe acute respiratory syndrome-associated coronavirus (SARS-CoV) is antigenic remains to be elucidated. Using Western blot and Enzyme-linked Immunosorbent Assay (ELISA), the recombinant N proteins and the synthesized peptides derived from the N protein were screened in sera from SARS patients. All patient sera in this study displayed strong positive immunoreactivities against the recombinant N proteins, whereas normal sera gave negative immunoresponses to these proteins, indicating that the N protein of SARS-CoV is an antigenic protein. Furthermore, the epitope sites in the N protein were determined by competition experiments, in which the recombinant proteins or the synthesized peptides competed against the SARS-CoV proteins to bind to the antibodies raised in SARS sera. One epitope site located at the C-terminus was confirmed as the most antigenic region in this protein. A detailed screening of peptide with ELISA demonstrated that the amino sequence from Codons 371 to 407 was the epitope site at the C-terminus of the N protein. Understanding of the epitope sites could be very significant for developing an effective diagnostic approach to SARS.
- [Show abstract] [Hide abstract]
ABSTRACT: In order to develop clinical diagnostic tools for rapid detection of the SARS-CoV (severe acute respiratory syndrome-associated coronavirus) and to identify candidate proteins for vaccine development, the C-terminal portion of the nucleocapsid (NC) gene was amplified using RT-PCR from the SARS-CoV genome, cloned into a yeast expression vector (pEGH), and expressed as a glutathione S-transferase (GST) and Hisx6 double-tagged fusion protein under the control of an inducible promoter. Western analysis on the purified protein confirmed the expression and purification of the NC fusion proteins from yeast. To determine its antigenicity, the fusion protein was challenged with serum samples from SARS patients and normal controls. The NC fusion protein demonstrated high antigenicity with high specificity, and therefore, it should have great potential in designing clinical diagnostic tools and provide useful information for vaccine development.
Top Journals
Beijing Genomics InstituteBao'an, Guangdong, China
Agricultural University Of HebeiPao-ting-shih, Hebei, China
University of Louisville
Louisville, Kentucky, United States
- Department of Medicine


text:
Photo of actual year not available
Drink Dates: 2012-2021
Professional content appears courtesy of Vinfolio
Firm, rich, intense and concentrated, this fragrant, well-structured red shows loamy earth, dried berry, mineral and cedar notes. Slow to unfold, this gains depth and dimension while retaining a tight framework.Drink Dates: 2011-2017
Professional content appears courtesy of Vinfolio
Deep ruby-red. Intense aromas of red berry preserves and cherry-cola, with complicating notes of dried rose, five-spice powder and white pepper. Ripe red berry flavors boast liqueur-like depth and intensity but there's an almost weightless quality to this wine that I find really intriguing, especially in light of its 16% (!) alcohol. Shows peppery spice and floral notes on the long, sappy, gently sweet finish.Author: Josh Raynolds
Professional content appears courtesy of Vinfolio
The 2009 Pinot Noir Moulin Rouge Pisoni Vineyard, which was harvested on September 6th, exhibits lots of dark blue and black raspberry fruit, some minerality, medium to full body, and a compact, still austere finish. It will benefit from more time in the bottle, and should drink well for 6-8 years.Drink Dates: 2013-2021
Professional content appears courtesy of Vinfolio
61 bottles owned by 25 collectors.
Since its founding in 2003, Vinfolio has brought the rarest and highest-quality wines to the collector market. Located in San Francisco and Napa, we are a company of wine experts who understand and value the importance of wine provenance. Our premium supplier relationships and first-in-class technology help us protect your wine from sourcing through shipping with extraordinary care that only we can provide. Don't trust your fine wine with anything less!Learn More

subset: commoncrawl


text:
Classics of the bar: stories of the world's great legal trials and a compilation of forensic masterpieces, Volume 6
Washington Law Book Co., 1942 - Speeches, addresses, etc., American
From inside the book
5 pages matching tartar emetic in this book
Where's the rest of this book?
Results 1-3 of 5
What people are saying - Write a review
We haven't found any reviews in the usual places.
Justinian in Council Frontispiece
The Trial of Ann K Simpson
The Munn Conspiracy Case
3 other sections not shown
Other editions - View all
Common terms and phrases
antimony arsenic authority believe Bolsheviks Borst called Carawan cause character charge Christison circumstances coffee color committed conduct conviction Coroner Croker counsel Court crime death deceased defendants delirium tremens District Attorney doubt dramshop Dream duty fact fatal fired friends Frohwerk gentlemen give guilty hand heard heart human husband innocent intemperance Jacob Rehm jail James O'Brien John McKenna jury justice kind knew Lassiter libel liquid tests Mallett McKenna ment mind Miss Arey Miss Register Mollie Steimer motive Munn murder nature never occasion opinion Orphan-Maker perjury phosphoric acid physicians pistol plaintiff precipitate present prisoner prisoner's produced proof prosecution prove republic of Russia Richard Croker Russia says shot sick Simpson Smith stand stomach swear syllabub symptoms Tammany Hall tartar emetic tell testified testimony thing tion told trial true truth United verdict wife Wilbar witness


text:
Lent has begun! Sign up today for a Lent devotional experience.
the vessel in which the dough, after being mixed and leavened, was left to swell or ferment (Ex. 8:3; 12:34; Deut. 28:5, 7). The dough in the vessels at the time of the Exodus was still unleavened, because the people were compelled to withdraw in haste.


text:
New York, NYUSA
August 25, 2012
I love to read and exchange on ideas.
I am open to most genres but particularly enjoy good literary fiction
Just moved here from the Bahamas.
Hello: I have just moved to Singapore and am looking forward to meeting new friends with likeminded interests.
Meetup members, Log in
By clicking "Sign up" or "Sign up using Facebook", you confirm that you accept our Terms of Service & Privacy Policy


text:
While many investors kept one eye on the Greek financial crisis and what might have been done by Germany, the European Central Bank and the International Monetary Fund to stave off any meltdown, the other eye was on the plethora of corporate earnings both this week and last.
Assembling and understanding what so many companies report can be daunting even for the professional investor and money managers, particularly when trying to gauge the underlying strength of the domestic economy. Based on company earnings, the majority of which have beaten Wall Street expectations, it would appear that things are getting better. I can say the majority because as of the end of last week 172 of the 500 companies that make up the S&P 500 had reported their earnings and, according to Thomson Reuters, a record 83 percent of those 172 had beaten Wall Street expectations (typically 61 percent of firms exceed expectations).
What that may or may not mean about analyst expectations is fodder for another day. The real question is whether or not companies beating Wall Street expectations means that things - the economy in general, the industry in which a company competes, or that company's position - are getting better.
The quick answer is "maybe; maybe not."
To say a company beat its earnings makes for a good headline but, as we know, we have to dig deeper to understand how a company gets such a "beat." There are several items we as investors need to watch out for - a gain or loss that is nonrecurring in nature, like the sale of a business or product line; an unexpectedly low tax rate that is not sustainable; ongoing cost containment that masks tepid revenue growth, and so on.
What it comes down to is breaking down a company's income statement and understanding the moving parts that compose its revenue line, cost structure above the operating income line as well as those parts between the operating income line and net earnings. Understanding these parts lets us understand the quality of a company's earnings.
A company that does better than expected with revenue and profit generation, with few one-time shenanigans to generate better than expected earnings per share is generally considered to be a solid "beat" with high-quality earnings. Companies that miss on the revenue line, artificially reduce operating expenses, benefit from an unsustainably low tax rate, tend to eke out performances in line with or slightly better than was forecast by Wall Street - they are viewed as having low-quality earnings.
As one can imagine, investors prefer companies with high-quality earnings and improving business over those with low-quality earnings and rocky prospects.
Back to all of those companies that have beaten expectations over the past few weeks. While I can't listen to all the earnings calls and review all the transcripts for all the companies that have so far delivered their March quarter results, of the ones I have, the vast majority have delivered good revenue performance and good cost containment.
That cost containment has largely been on operating-expense items, though predominantly through head count reduction over the last several quarters. I mention "head count" here because the question of jobs and job growth is rather important. As I type this, initial jobless claims for this week of 448,000 were modestly higher than economists were expecting, but the fresh weekly claims remain at elevated levels.
With regard to head-count reductions and company earnings, the question I ask as an investor is "how much more cost cutting can be done?" As the popular expression goes, past a certain point you stop cutting the fat and start cutting into the muscle.
There is a larger concern that I have surrounding the risk of a rising-cost structure and what it means not only for earnings but also for a company's ability to beat earnings expectations in the coming quarters. On the one hand, the domestic economy is improving, as recent commentary from the Federal Reserve underscores. Eventually this should drive some job growth, which would add to a company's cost structure incrementally, particularly when we consider the full cost of employing a person for salary and benefits.
At the same time, there are growing data that show input costs are rising as well. Oil, gas and other commodities. Rising meat prices as pork, beef and chicken prices have all moved higher with several food economists calling for record prices in the coming months. These and other inputs are likely to have a ripple effect, especially given the wide reach of petroleum in the factory as well as in and around the home, car and elsewhere on both a direct and indirect basis. Already inflation in producer prices is being reported in Australia and there is growing concern that China's economy may be overstimulated.
How long until the talk of inflation rears it head again? Mix that with lingering high unemployment and stir. My advice - focus on companies with those high-quality earnings because those low-quality earnings companies might be in for a tougher ride going forward. All that and we did not touch on what rising input costs may mean amid high unemployment and tepid consumer spending in our current economic recovery. More as it develops.
• Chris Versace is director of research at Think 20/20 LLC, an independent research and corporate access firm based in Reston, Va. He can be reached at cversace@washington times.com. At the time of publication, Mr. Versace had no positions in companies mentioned. However, positions can change.


text:
Interval Leisure Group, Inc. (IILG)
Industry: Finance
Community Rating:
Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Symbol Lookup
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Interval Leisure Group (IILG)
Q1 2013 Earnings Call
May 06, 2013 4:30 pm ET
Jennifer Klein Trager
Craig M. Nash - Chairman, Chief Executive Officer, President and Member of Executive Committee
William L. Harvey - Chief Financial Officer and Executive Vice President
Charles Patrick Scholes - SunTrust Robinson Humphrey, Inc., Research Division
Stephen Altebrando - Sidoti & Company, LLC
Nikhil Bhalla - FBR Capital Markets & Co., Research Division
» Bridgepoint Education Management Discusses Q1 2013 Results - Earnings Call Transcript
» Century Casinos CEO Hosts Annual General Meeting (Transcript)
Jennifer Klein Trager
Thank you, Derick, and good afternoon to everyone on the call. Welcome to the Interval Leisure Group First Quarter 2013 Earnings Conference Call. I want to remind you that on our call today, we will discuss our outlook for future performance. These forward-looking statements typically are preceded by words such as we expect, we believe, we anticipate or similar statements. These forward-looking statements are subject to risks and uncertainties, and our actual results can differ materially from the views expressed today. Some of these risks have been set forth in our first quarter 2013 press release issued earlier today and in our 2012 Form 10-K and other periodic reports filed with the SEC. We will also discuss certain non-GAAP measures. I refer you to our press release posted on our website at www.iilg.com for all comparable GAAP measures and full reconciliation.
And now, I'd like to turn the call over to Craig Nash, our Chairman, President and Chief Executive Officer. Craig?
Craig M. Nash
Thanks Jennifer and good afternoon to everyone. Thank you for joining us for Interval Leisure Group's First Quarter 2013 Earnings Conference Call. Once again, ILG reported positive top and bottom line results, driven by our strategic initiatives and execution across our businesses.
Interval Leisure Group's consolidated revenue for the quarter increased by more than 6% from the prior year. Earnings per share increased 63% and adjusted EBITDA was up nearly 7%.
The Management and Rental segment remains a source of growth within our company. Revenue was up nearly 27%, reflecting the contribution from Vacation Resorts International, which we acquired at the end of February 2012. Management fee and rental revenue grew at an impressive 40%.
More telling, is the success we've had in improving gross margin in this area. Excluding the past revenue, gross margins for this segment was 68% in the first quarter compared to 65.7% last year.
Technology has been a focus for Aston. We have been investing in software and hardware that will allow us to improve most facets of our property management infrastructure. This should further our efforts to control costs, while optimizing yield for owners and managed properties.
In the Membership and Exchange segment, revenue saw a modest uptick that was driven by 2.3% increase in membership fee revenue. The Interval Network saw a slight decline in total active members. This is due to the impact of fewer new members entering from the point-of-sale when compared to last year. If you recall, we added a large block of corporate members in the first quarter of 2012.
During the quarter, Interval International added 36 resorts to its extensive network. Notable affiliations announced during the quarter included Royal Results Caribbean collection, a points-based vacation club and the Morritt's Tortuga Club in Grand Cayman. This property includes 131 existing units and 20 new luxury suites that are currently under construction. With more than 20% of our new affiliations for the quarter, Latin America has become one of the most promising regions for growth. Interval work with Ipsos Research to study the market for shared ownership in Colombia and Brazil. The results of these studies clearly show that the expanding middle class in these countries is attracted to the shared ownership concept. Interval's commitment to improving service levels puts members and developer clients is demonstrated by our investment in leading-edge technology.
Launched this spring, the Interval Sales Tool Kit App leverages the growing popularity of using an iPad at the point-of-sale to create a more impactful exchange presentation. A key feature is the Interval Exchange Tracker, an interactive world map that animates exchange vacations that have been booked by members in the previous 24 hours. Since industry research reinforces that exchange is a top initial purchase motivator, this app brings to life the world of vacation possibilities available through Interval International. This tool was extremely well received by our clients at the annual ARDA conference in March.
Additionally, Interval has added digital tools for members with the advanced -- enhanced Interval International app, which has now gives them the ability to purchase Getaways. They're also able to log in while on the go to access account information, browse the resort directory and share information with family and friends on social networks. Updates have also been made to the user-friendly consumer website IntervalWorld.com. Additionally, we now have the moble version of the site which gives our members a variety of ways to transact with Interval.
Our ongoing commitment to web-based services has resulted in a 50% increase in online confirmations from 2007 to 2012. Our investments in mobile platforms will serve the growing number of members who research or book their vacations on a smartphone or tablet device.
Read the rest of this transcript for free on seekingalpha.com


text:
LabKey Software Foundation
Docs & Support
Sign In
Start Page
Start Page
FAQ - Frequently Asked Questions
Who uses LabKey?
Please see
Platform Users
for a representative list. To further explore usage of LabKey Server, see our
list of publications
and our
showcase of public sites
Who builds LabKey?
LabKey software is designed by the researchers who use it, working in collaboration with professional software developers. Many, but not all, of the developers work for LabKey Software (
), a company founded by FHCRC and former FHCRC employees, based in Seattle, WA. Publications authored by the LabKey team are available
When will the next version be released?
Approximate release dates can be found in our
release schedule
Who owns the software?
The vast majority of code developed by LabKey Corporation is licensed under
Apache License 2.0
, with premium features licensed under a separate LabKey license. Developers who contribute source code to the project make a choice to either maintain ownership of their code (signified via copyright notice in the source code files) or assign copyright to LabKey Corporation. Source code contributors grant a perpetual transferable license to their work to the community under terms of the Apache License.
Why use the Apache License?
The Apache License is a broadly used, commerce-friendly open source license that provides maximum flexibility to consumers and contributors alike. In particular, anyone may modify Apache-licensed code and redistribute or resell the resulting work without being required to release your modifications as open source.
Do I need to cite LabKey Server?
If you use LabKey Server for your work, we request that you
cite LabKey Server
in relevant papers.
How can I get involved?
There are many ways to get involved with the project. Researchers can download and evaluate the software. You can join
community forums
for Proteomics, Flow Cytometry, and Study. Java Developers can enlist in the project, set up the build environment, and join the Developers Center. Research networks, laboratories, foundations, and government funding agencies can sponsor future development. Software vendors can develop proprietary modules. Developers interested in building from source or creating new modules should visit the
Developer Center
Who funds LabKey's development?
LabKey has been built under contract with FHCRC, NCI, The Canary Foundation, Duke University, NIAID, the Bill and Melinda Gates Foundation, Cedars-Sinai Medical Center, the Immune Tolerance Network, the University of Washington, and others. In most cases funding agencies sponsor investigators using ordinary granting mechanisms, and the investigators contract with LabKey Software to extend the software to meet their lab's needs. Most extensions are then bundled into the core distribution and re-licensed for free with source code back to the community.
What language is the software written in?
The software is written in Java and runs on most modern operating systems, including Windows, Linux, Solaris, and Mac OSX. It can be customized and extended by skilled Java programmers.
How mature is the software?
First deployed in 2004, the system is in heavy production use and under active development. New versions are released three times per year. Existing installations can be upgraded in place to new versions. Scientific modules generally evolve through a 4-phase life cycle: design development, single-lab deployment, limited multi-lab deployment, and production release.
How is the software constructed?
The system includes a set of core shared services such as security, web-based user interface, and relational database access. Independent modules provide scientific functionality for proteomics, client & observational study management, flow cytometry, Elisa, Luminex, NAb, microarray, and DNA sequencing. New modules are added every release.
How much does it cost?
All source code distributed with the Community Edition is free. Third-parties can provide binary distributions with or without modifications under any terms that are consistent with the Apache License.
LabKey Software
provides Community Edition binary distributions for free. Premium Editions of LabKey Server are paid subscriptions that provide additional functionality to help teams optimize workflows, securely manage complex projects and explore multi-dimensional data. These Premium Editions also include LabKey Software's professional support services and allow our experts to engage with your team as long-term partners committed to the success of your informatics solutions.
What equipment do I need to run LabKey?
LabKey acts as a web server and relies on a relational database server. It can be installed and run on a stand-alone PC, but is most commonly deployed in production in a networked server environment. Single laboratory installations can be run on a single dedicated computer. Core proteomics facilities use LabKey to manage cluster pipelines with hundreds of machines.
How can I find documentation for older versions of LabKey Server?
See the links below for release notes from previous versions and archived documentation:
Release Notes Archive
Documentation Archive
Do you have a press contact?
For media and conference inquiries about LabKey Server, please contact:
Michael Gersch
(206) 489-2578
Install LabKey Server (Quick Install)
What's New in 15.3?
Release Notes 15.3
What's Next?
Platform Overview
FAQ - Frequently Asked Questions
Platform Users
Showcase of Installations
How to Cite LabKey Server
LabKey Terminology/Glossary
Archive: Documentation
What's New in 15.2?
Release Notes 15.2
What's New in 15.1?
Release Notes 15.1
LabKey Argos
What's New in 14.3?
Release Notes 14.3
What's New in 14.2?
Release Notes 14.2
What's New in 14.1?
Release Notes 14.1
What's New in 13.3?
Release Notes 13.3
What's New in 13.2?
Release Notes 13.2
Learn What's New in 13.1
Release Notes 13.1
Video Demonstrations 13.1
New Feature "Sprint" Demos
Learn What's New in 12.3
Release Notes 12.3
12.3 Video Demonstrations
Learn What's New in 12.2
Release Notes 12.2
12.2 Video Demonstrations
Learn What's New in 12.1
12.1 Release Notes
12.1 Video Demonstrations
Learn What's New in 11.3
11.3 Release Notes
11.3 Video Demonstrations
Learn What's New in 11.2
11.2 Release Notes
11.2 Video Demonstrations
Learn What's New in 11.1
11.1 Release Notes
11.1 Release Webinar
Learn What's New in 10.3
10.3 Release Notes
Learn What's New in 10.2
10.2 Release Notes
Learn What's New in 10.1
10.1 Release Notes
Learn What's New in 9.3
9.3 Upgrade Tips
Learn What's New in 9.2
9.2 Upgrade Tips
Learn What's New in 9.1
9.1 Upgrade Tips
Learn What's New in 8.3
Learn What's New in 8.2
8.2 Upgrade Tips
Learn What's New in 8.1
8.1 Upgrade Tips
Learn What's New in 2.3
Learn What's New in 2.2
Learn What's New in 2.1
Learn What's New in 2.0
Integrating Heterogeneous Data
Study Properties
Demographic Data
Clinical Data
Specimen Data
Assay Data
Cohorts and Participant Groups
Release Notes 16.1
Tutorial: Security
Step 1: Configure Permissions
Step 2: Test Security with Impersonation
Step 3: Audit User Activity
Step 4: Handle Protected Health Information (PHI)
Projects and Folders
Navigate Site
Project and Folder Basics
Site Structure: Best Practices
Manage Projects and Folders
Create a Project or Folder
Move, Delete, Rename Projects and Folders
Enable a Module in a Folder
Export / Import a Folder
Export and Import Permission Settings
Manage Email Notifications
Define Hidden Folders
Folder Types
Community Modules
Establish Terms of Use
Configure Permissions
Security Groups
Global Groups
Project Groups
Site Groups
Guests / Anonymous Users
Security Roles Reference
Site Administrator
Matrix of Report and View Permissions
Role / Permissions Table
User Accounts
Add Users
Manage Users
My Account
Manage Project Users
Configure Database Authentication
Password Reset & Security
Configure LDAP
Configure CAS Single Sign On Authentication
Configure Duo Two Factor Authentication
Create a .netrc or _netrc file
HTTP Basic Authentication
Test Security Settings by Impersonation
Admin Console
Site Settings
Look and Feel Settings
Web Site Theme
Email Customization
Experimental Features
Manage Missing Value Indicators / Out of Range Values
Short URLs
Configure System Maintenance
Configure Scripting Engines
Audit Site Activity
SQL Query Logging
Actions Diagnostics
Cache Statistics
Dump Heap
Memory Usage
Running Threads
Query Performance
Site/Container Validation
Install LabKey
Installation Basics
Install LabKey Server (Windows Graphical Installer)
Install LabKey Manually
Install Required Components
Configure the LabKey Web Application
labkey.xml Configuration File Reference
Third-Party Components and Licenses
Install a Remote Pipeline Server via the Windows Installer
Supported Technologies
Troubleshoot Installation
Installation Error Messages
Dump Memory and Thread Usage Debugging Information
Common Install Tasks
Install Microsoft SQL Server
Install PostgreSQL (Windows)
Install PostgreSQL (Linux, Unix or Macintosh)
Install LabKey Server on Solaris
Notes on Installing PostgreSQL on All Platforms
Install and Set Up R
Determine Available Graphing Functions
Install SAS/SHARE for Integration with LabKey Server
Configure Webapp Memory
Set Up Robots.txt and Sitemaps
GROUP_CONCAT Install
Example Setups and Configurations
Set up a JMS-Controlled Remote Pipeline Server
Example Installation of Flow Cytometry on Mac OSX
Configure R on Linux
Configure the Virtual Frame Buffer on Linux
Example Linux Installation
DEPRECATED: Install LabKey Server (Linux Installer)
Upgrade LabKey
Manual Upgrade Checklist
Manual Upgrade Script for MacOSX, Solaris and Unsupported Linux Distributions
DEPRECATED: Upgrade LabKey via the Linux Installer
Upgrade Support Policy
Backup and Maintenance
Backup Checklist
A Sample Backup Plan
Sample Scripts for Backup Scenarios
PostgreSQL Maintenance
Administer the Site Down Servlet
Staging, Test and Production Servers
Example of a Large-Scale Installation
Tips for Configuring a Staging Server
Collaboration Tutorial
Step 1: Use the Message Board
Step 2: Collaborate Using a Wiki
Step 3: Track Issues
File Repository Tutorial
Step 1: Set Up a File Repository
Step 2: File Repository Administration
Step 3: Search the Repository
Step 4: Import Data from the Repository
Step 5: Advanced Search and Keywords (Optional)
Upload Files
Share and View Files
File Sharing and URLs
Import Data from Files
File Administrator Guide
Files Web Part Administration
Upload Files: WebDAV
Set File Roots
Troubleshoot File Roots and Pipeline Overrides
File Terminology
Integrating S3 Cloud Data Storage
Data Processing Pipeline
Set a Pipeline Override
Enterprise Pipeline
Install Prerequisites for the Enterprise Pipeline
JMS Queue
RAW to mzXML Converters
Configure LabKey Server to use the Enterprise Pipeline
Configure the Conversion Service
Configure Remote Pipeline Server
Configure Pipeline Path Mapping
Use the Enterprise Pipeline
Troubleshoot the Enterprise Pipeline
Use Message Boards
Administer Message Boards
Wiki Admin Guide
Copy Wiki Pages
Wiki User Guide
Wiki Syntax
Wiki Syntax: Macros
Special Wiki Pages
Embed Live Content in Wiki Pages or Messages
Examples: Embedded Web Parts
Search Documentation
Add Screenshots to a Wiki
Manage Wiki Attachment List
Wiki: Discussion Link
Issue/Bug Tracking
Using the Issue Tracker
Administering the Issue Tracker
Electronic Data Capture (EDC)
Survey Designer: Basics
Survey Designer: Customization
Survey Designer: Reference
Survey Designer: Example Questions
REDCap Survey Data Integration
Adjudication Module
Set Up an Adjudication Folder
Initiate an Adjudication Case
Record an Adjudication Determination
Monitor Adjudication
Data and Views
Build User Interface
Add Web Parts
Manage Web Parts
Web Part Inventory
Use Tabs
Add Custom Menus
Web Parts: Permissions Required to View
Data Grids
Data Grids: Basics
Sort Data
Filter Data
Select Rows
Customize Views
Saved Filters and Sorts
Join Columns from Multiple Tables
Lookup Columns
Export Data
Participant Views
Query Scope: Filter by Folder
Field Properties Reference
URL Field Property
Conditional Formats
Date & Number Display Formats
Date and Number Formats Reference
Reports, Views, and Charts
Display a Report or View
Data Views Browser
Manage Reports and Views
Manage Categories
Manage Thumbnail Images
Attachment Reports
Box Plots
Link Reports
Participant Reports
Query Report
Query Snapshot
Quick Charts
R Reports
R View Builder
Saved R Views
Datasets in R
Multi-Panel R Plots
Lattice Plots
Participant Charts in R
R Reports with knitr
Input/Output Substitutions Reference
FAQs for LabKey R Views
R Tutorial Video
Scatter Plots
Time Charts
Why Is a Column Not Available for Charting?
Legacy Reports
Advanced Views / External Reports
Chart Views
Crosstab Views
SQL Queries
LabKey SQL Tutorial
SQL Query Browser
LabKey SQL Reference
Lookups: SQL Syntax
Create a SQL Query
Edit SQL Query Source
Query Metadata
Edit Query Properties
Display a Query
Add a Calculated Column to a Query
Create a Pivot Query
Parameterized SQL Queries
SQL Examples: JOIN, Calculated Columns, GROUP BY
Cross-Folder Queries
SQL Synonyms
External Schemas and Data Sources
External MySQL Data Sources
External Oracle Data Sources
External Microsoft SQL Server Data Sources
External PostgreSQL Data Sources
External SAS Data Sources
Linked Schemas and Tables
Manage Remote Connections
LabKey Data Structures
Preparing Data for Import
List Tutorial
List Tutorial: Set Up
Create a Joined View to Investigate Results
Add a URL Property
Create and Populate Lists
Create a List by Defining Fields
Populate a List
Import a List Archive
Manage Lists
Connect Lists
Edit a List Design
Choose a Primary Key
Search Administration
Natural Language Processing Pipeline (NLP)
Configure Natural Language Processing
Process Files Using Natural Language Processing
Instrument Data
Tutorial: Design a General Purpose Assay (GPAT)
Assay Tutorial Set Up
Infer an Assay Design from Spreadsheet Data
Import Assay Data
Work with Assay Data
Data Validation
Integrate Assay Data into a Study
ELISA Assay Tutorial
ELISpot Assay
ELISpot Assay Tutorial
Import ELISpot Data
Review ELISpot Data
ELISpot Properties
FluoroSpot Assay
NAb (Neutralizing Antibody) Assays
NAb Assay Tutorial
Create a NAb Assay Design
Import NAb Assay Data
View High-Throughput NAb Data
Explore NAb Graph Options
Use NAb Data Identifiers
Work with Low-Throughput NAb Data
Work with Multiple Viruses per Plate
NAb Plate File Formats
Customize NAb Plate Template
NAb Properties
Luminex® Assay Tutorial Level I
Setup Luminex® Tutorial Project
Create a New Luminex® Assay Design
Import Luminex® Run Data
Exclude Analytes for QC
Import Multi-File Runs
Copy Luminex® Data to Study
Luminex® Assay Tutorial Level II
Import Lists and Assay Archives
Configure R, Packages and Script
Import Luminex® Runs
View 4pl and 5pl Curve Fits
Track Analyte Quality Over Time
Use Guide Sets to Show Expected Ranges
Compare Standard Curves Across Runs
Track Single-Point Controls in Levey-Jennings Plots
Luminex® Reference
Review Luminex® Assay Design
Luminex® Properties
Luminex® file formats
Import Luminex Runs
Review Well Roles
Luminex Calculations
Luminex Conversions
Luminex QC Reports and Flags
Customize Luminex Assay for Script
Review Fields for Script
Troubleshoot Luminex® Transform Scripts and Curve Fit Results
Flow Cytometry
LabKey Flow Module
Supported FlowJo Versions
Flow Cytometry Overview
Tutorial: Import a Flow Workspace
Set up a Flow Folder
Upload Files to Server
Import a Flow Workspace and Analysis
FCS File Resolution
Customize Your View
Examine Graphs
Examine Well Details
Finalize a Dataset View and Export
Tutorial: Perform a LabKey Flow Analysis
Define a Compensation Calculation
Define an Analysis
Apply a Script
View Results
Add Sample Descriptions
Custom Flow Queries
Add Statistics to FCS Queries
Calculate Suites of Statistics for Every Well
Flow Module Schema
Analysis Archive Format
FCS Express
Tutorial: Import Flow Data from FCS Express
Reagent Inventory
FCS keyword utility
Flow Team Members
Microarray Assay Tutorial
Expression Matrix Assay Tutorial
Microarray Properties
Proteomics Tutorial
Set Up for Proteomics Analysis
Search mzXML Files
View PeptideProphet Results
View ProteinProphet Results
Compare Runs
Search for a Specific Protein
Proteomics Video
Get Started With LabKey Proteomics
Explore the MS2 Dashboard
Search MS2 Data Via the Pipeline
Set Up MS2 Search Engines
Set Up Mascot
Set Up Sequest
Set Up Comet
Working with mzML files
Set the LabKey Pipeline Root
Search and Process MS2 Data
Configure Common Parameters
Configure X! Tandem Parameters
Configure Mascot Parameters
Configure Sequest Parameters
Sequest Parameters
MzXML2Search Parameters
Examples of Commonly Modified Parameters
Configure Comet Parameters
Import Existing Analysis Results
Launch MS2 pipeline jobs when files are available
Change the versions of the proteomics search tools used by the pipeline
Work with MS2 Runs
View an MS2 Run
Customize Display Columns
Peptide Columns
Protein Columns
View Peptide Spectra
View Protein Details
View Gene Ontology Information
Compare MS2 Runs
Compare ProteinProphet
Export MS2 Runs
Export Spectra Libraries
View, Filter and Export All MS2 Runs
Protein Search
Peptide Search
Loading Public Protein Annotation Files
Using Custom Protein Annotations
Using ProteinProphet
Using Quantitation Tools
Experimental Annotations for MS2 Runs
Protein Expression Matrix Assay
Link Protein Expression Data with Annotations
Exploratory Features
Spectra Counts
Label-Free Quantitation
Combine XTandem Results
MS1 Pipelines
Panorama - Targeted Proteomics
Configure Panorama Folder
Panorama QC Dashboard
Panorama Quality Control
Panorama Document Revision Tracking
Proteomics Team
Genomics Workflows
Set Up a Genotyping Dashboard
Example Workflow: LabKey and Galaxy
Example Workflow: LabKey and Illumina
Example Workflow: LabKey and PacBio
Example Workflow: O'Connor Module
Import Haplotype Assignment Data
Work with Haplotype Assay Data
Illumina Properties
Assay Administrator Guide
Set Up Folder For Assays
Assay Designs and Types
Import Assay Design
Design a New Assay
General Properties
Design a Plate-Based Assay
Edit Plate Templates
Participant/Visit Resolver
Manage an Assay Design
Improve Data Entry Consistency & Accuracy
Set up a Data Transformation Script
Integrate Assay Data into a Study
Copy-To-Study History
Experiment Descriptions & Archives (XARs)
Experiment Terminology
Samples and Sample Sets
Run Groups
XAR File Tutorial
Uses of XAR.xml Files
Import a XAR.xml
Troubleshoot XAR Import
Import XAR Files Using the Data Pipeline
Example 1: Review a Basic XAR.xml
Examples 2 & 3: Describe Protocols
Examples 4, 5 & 6: Describe LCMS2 Experiments
Design Goals and Directions
Life Science Identifiers (LSIDs)
LSID Substitution Templates
Assay User Guide
Import Assay Runs
Electronic Laboratory Notebooks (ELN)
Data Integration
Study Tour
Tutorial: Cohort Studies
Step 1: Install the Sample Study
Step 2: Study Data Dashboards
Step 3: Integrate Data from Different Sources
Step 4: Compare Participant Performance
Tutorial: Set Up a New Study
Step 1: Define Study Properties
Step 2: Import Datasets
Step 3: Assign Cohorts
Step 4: Import Specimens
Step 5: Enable Comments
Study User Guide
Study Navigation
The Study Navigator
Study Data Browser
Participant Groups
Dataset Quality Control States
Study Administrator Guide
Create a Study
Create and Populate Datasets
Create a Dataset from a File
Create a Dataset by Defining Fields
Create Multiple Dataset Definitions from a TSV File
Import Data to a Dataset
Import Through the Files Web Part
Import via Copy/Paste
Import From a Dataset Archive
Create Pipeline Configuration File
Import Study Data From REDCap Projects
Edit Dataset Properties
Dataset Fields Reference
Pre-Defined Fields
Dataset Properties Reference
Use Visits or Timepoints
Create Visits
Edit Visits or Timepoints
Import Visit Map
Import Visit Names / Aliases
Manage a Study
Custom Study Properties
Manage Datasets
Manage Visits or Timepoints
Study Schedule
Manage Locations
Manage Cohorts
Manage Participant IDs
Alternate Participant IDs
Alias Participant IDs
Manage Comments
Manage Study Security (Dataset-Level Security)
Configure Permissions for Reports & Views
Matrix of Permissions
Securing Portions of a Dataset (Row and Column Level Security)
Manage Dataset QC States
Manage Study Products
Manage Treatments
Manage Assay Schedule
Demonstration Mode
Create a Vaccine Study Design
Continuous Studies
Import, Export, and Reload a Study
Export Study Objects
Study Import/Export Files and Formats
Serialized Elements and Attributes of Lists and Datasets
Publish a Study
Publish a Study: Protected Health Information
Publish a Study: Refresh Snapshots
Ancillary Studies
Shared Datasets and Timepoints
Data Aliasing
Specimen Request Tutorial
Specimen Tutorial: Repository Set Up (Admin)
Specimen Tutorial: Request System (Coordinator)
Specimen Tutorial: Request Specimens (User)
Specimen Tutorial: Track Requests (Coordinator)
Specimen Administrator Guide
Import Specimen Spreadsheet Data
Import a Specimen Archive
Specimen Archive File Reference
Specimen Archive Data Destinations
Troubleshoot Specimen Import
Import FreezerPro Data
Specimen Properties and Rollup Rules
Customize Specimens Web Part
Flag Specimens for Quality Control
Edit Specimen Data
Customize the Specimen Request Email Template
Export a Specimen Archive
Specimen Coordinator Guide
Email Specimen Lists
View Specimen Data
Generate Specimen Reports
Laboratory Information Management System (LIMS)
LabKey Client APIs
JavaScript API
Tutorial: Create Applications with the JavaScript API
User Interface: Request Form
Confirmation Page
R Histogram (Optional)
Summary Report For Managers
Repackaging the App as a Module
Tutorial: Use URLs to Filter and Pass Data
Choose Parameters
Show Filtered Grid
Tutorial Video: Building Reports and Custom User Interfaces
JavaScript API - Samples
JavaScript Views
Export Data Grid as a Script
Export Chart as JavaScript
Custom HTML/JavaScript Participant View
Custom Button Bars
Web Part Configuration Properties
Insert into Audit Table via API
Declare Script Dependencies
Loading ExtJS On Each Page
Licensing for the ExtJS API
Search API Documentation
Naming & Documenting JavaScript APIs
Naming Conventions for JavaScript APIs
How to Generate JSDoc
JsDoc Annotation Guidelines
Java API
Prototype LabKey JDBC Driver
Remote Login API
Security Bulk Update via API
Perl API
Python API
Rlabkey Package
Troubleshooting Rlabkey Connections
SAS Macros
SAS Setup
SAS Macros
SAS Security
SAS Demos
HTTP Interface
Examples: Controller Actions
Example: Access APIs from Perl
Develop Modules
Tutorial: Hello World Module
Map of Module Files
Example Modules
Modules: Queries, Views and Reports
Module Directories Setup
Module Query Views
Module SQL Queries
Module-Based Queries: Metadata
Module R Reports
Module-Based Reports: Metadata
Module HTML and Web Parts
Providing a Custom Footer
Module Database Transition Scripts
Modules: Assay Types
Tutorial: Define an Assay Type in a Module
Assay Custom Domains
Assay Custom Views
Example Assay JavaScript Objects
Assay Query Metadata
Customize Batch Save Behavior
SQL Scripts for Module-Based Assays
Transformation Scripts
Example Workflow: Develop a Transformation Script (perl)
Example Transformation Scripts (perl)
Transformation Scripts in R
Transformation Scripts in Java
Transformation Scripts for Module-based Assays
Run Properties Reference
Transformation Script Substitution Syntax
Warnings in Tranformation Scripts
Modules: ETLs
Tutorial: Extract-Transform-Load (ETL)
ETL Tutorial: Set Up
ETL Tutorial: Run an ETL
ETL Tutorial: Create a New ETL
ETL: User Interface
ETL: Schedules and Options
ETL: Column Mapping
ETL: Queue an ETL From Another ETL
ETL: Stored Procedures
ETL: Stored Procedures in MS SQL Server
ETL: Functions in PostgreSQL
ETL: Check For Work From a Stored Procedure
ETL: SQL Scripts
ETL: Remote Connections
ETL: Logs and Error Handling
ETL: All Jobs History
ETL: Examples
ETL: Reference
Modules: Java
Module Architecture
Getting Started with the Demo Module
Creating a New Java Module
The LabKey Server Container
Implementing Actions and Views
Implementing API Actions
Integrating with the Pipeline Module
Integrating with the Experiment Module
Using SQL in Java Modules
GWT Integration
GWT Remote Services
Java Testing Tips
HotSwapping Java classes
Deprecated Components
Modules: Folder Types
Modules: SQL Scripts
Deploy Modules to a Production Server
Reloading Modules
Upgrade Modules
Main Credits Page
Module Properties Reference
Common Development Tasks
Trigger Scripts
Availability of Server-side Trigger Scripts
Script Pipeline: Running R and Other Scripts in Sequence
LabKey URLs
URL Actions
How To Find schemaName, queryName & viewName
LabKey Keys
LabKey/Rserve Setup Guide
Context Paths: contextPath, containerPath, webpartContext
Web Application Security
HTML Encoding
Cross-Site Request Forgery (CSRF) Protection
LabKey Open Source Project
Source Code
Release Schedule
Issue Tracker
LabKey Scrum FAQ
Developer Email List
Branch Policy
Test Procedures
Running Automated Tests
Hotfix Policy
Feature Owners
Previous Releases
Previous Releases -- Details
Submit Contributions
Confidential Data
CSS Design Guidelines
UI Design Patterns
Design Guidelines Supplemental
Documentation Style Guide
Check in to the Source Project
Renaming files in Subversion
Set up a Development Machine
Creating Production Builds
Enlisting in the Version Control Project
Enlisting Proteomics Binaries
Customizing the Build
Machine Security
Notes on Setting up a Mac for LabKey Development
Developer Reference
Products and Services
LabKey Server Editions
Custom Community Modules
LabKey Argos
Argos Tour
LabKey NLP
LabKey Biologics
Panorama Partners Program
expand all
collapse all
Powered by LabKey Software


text:
On Things I've Written by KiriskaWatch
©2013-2016 Kiriska
Know that feeling. Though, I wasn't writing fanfiction at that time.... And its still not good....
Aw come on, no shame in the first draft!
I... I mean.. I know the feeling. (heh. Awkward moment there)
Haha, I had to think a moment before I even realized the other implication. XD IT'S ALL GOOD~.
So true XD


text:
CRANSTON, R.I. � Corrections Director A.T. Wall has asked the Rhode Island State Police to investigate allegations of potential criminal activity by several key Department of Corrections staff members, he said in a news release Wednesday.
�I have been briefed on a regular basis by my Internal Affairs Unit since I ordered an investigation into allegations of misconduct by several key staff members at the Department of Corrections,� he wrote. �At our most recent meeting, I learned that some of the actions alleged may indicate criminal activity.�
On �March 18 Wall said the internal investigation involved reports that there was a seance held in an official�s office.
Wall said the State Police superintendent, Col. Steven O�Donnell, had agreed that his department would investigate.
�Our inspectors will assist State Police officials as they look into the matter. In order to protect the integrity of their investigation, henceforth any inquiries should be directed to the State Police.
Location, ST | website.com


text:
BNP Paribas Employee Just Earned Himself A Starring Role In Michael Lewis's Next Book
It's about lowlives who spread falsehoods about Michael Lewis, with a subplot about the guy's […]
Pimco Trustees who have no idea who they're fucking with
Pimco Trustee Dares To Question American Thoroughbred's Annual Compensation
Bill Gross set to blow again in 5…4…3…2…
Dealbreaker Event: "Town Maul 2016″
We want to invite you out for a night of drinking and yelling that we're hosting alongside our bros at Above the Law. Join us on Feb 18th in NYC for an open bar and a short panel discussion featuring special guests! Think of it as a boozy safe space to defend your role in the destruction of America.
Area List-Maker Too Good For Steve Cohen
Yesterday we highlighted a group of people who, despite all that has gone down, still […]
Charlie Ergen Not Sure Phil Falcone Really Wants To Go There
As some of you may recall, back in August, when Phil Falcone was on a […]
How Your Fiscal Cliff Deal Sausage Gets Made
John Boehner Is Sorry He's Not Sorry
House Speaker John Boehner couldn't hold back when he spotted Senate Majority Leader Harry Reid […]
Columbia University Students, Faculty, Alums Demand CU President Take Back All The Nice Things He Said About Jamie Dimon
As you may have noticed, Jamie Dimon has had some unwanted attention thrown his way over the last several weeks, on account of one of his employees losing a few billion dollars. Though the JPMorgan CEO has been dealing with public displays of hate previously reserved for Lloyd Blankfein and Goldman Sachs, and will certainly be on the receiving end of a lot more tomorrow when he testifies on Capitol Hill, he has had a few people come to his (and his bank's) defense. Yesterday Stephen Schwarzman told Bloomberg to lay off JD and JPM, noting that "occasional losses are inevitable" and "publicly excoriating JPMorgan serves no purpose except to reduce people's confidence in the financial system," while former Goldman exec Bill Archer said the whale fail makes him just "kind of shrug." Lee Bollinger, who is President of Columbia and chairman of the Federal Bank of New York's board of directors told the Journal that Dimon shouldn't step down from his post as a director, as some have requested, and that those who cite conflicts of interest have a "false understanding of how [the Fed] works." Some individuals from the Columbia community read Bollinger's comment and, spoiler alert, are not happy. Enter, a strongly worded letter.
Mr. Lee Bollinger
President of Columbia University
Office of the President
202 Low Library
535 West 116th Street, Mail Code 4309
New York, NY 10027
Dear President Bollinger,
As faculty, alumni and students of Columbia University, we are writing to express our deep disappointment in your recent decision to support JPMorgan Chairman and CEO Jamie Dimon's continued membership on the Board of the New York Federal Reserve Bank.
As the Chairman of the Board of the New York Fed, your unambiguous duty – as stated by the Guide to Conduct – is to maintain "the integrity, dignity, and reputation of the Federal Reserve System . . . and to avoid actions that might impair the effectiveness of System operations or in any way tend to discredit the System."
By supporting Mr. Dimon's tenure you abdicated this basic responsibility. By echoing Mr. Ben Bernanke's remarks that it is up to Congress to address this problem, you denied your duty to ensure the integrity of the Fed. By stating that Congress has more pressing issues to address than this one, you, in essence, urged inaction by all parties capable of affecting this important change. Surely you understand that a functioning financial system is a pre-requisite of our country's economic recovery. By characterizing those who wish to see Mr. Dimon resign as "foolish" and in possession of a "false understanding" of how the Fed works, you have added insult – and inaccuracy – to the injury of encouraging this institution to continue in its current form.
It is worth reminding you that JPMorgan Chase is currently under investigation for its recent $3 billion trading loss – a loss Mr. Dimon initially denied and then characterized as a 'tempest in a teapot.' It may also bear repeating that Mr. Dimon has long campaigned aggressively against important regulatory reforms designed to prevent excessive risk taking by Too Big To Fail institutions – institutions the Federal Reserve saved with $3 trillion dollars in special lending facilities and which Congress bailed out with $700 billion of taxpayers' money. Certainly Mr. Dimon has no place as a leader of this institution.
We urge you to reverse your support for Mr. Dimon and call for his immediate resignation. By way of reminder, there is precedent for this kind of action. In April 2011, Jeffrey R. Immelt, CEO of General Electric, stepped down from the NY Fed after it was clear that GE Capital would be regulated by the Fed as a 'systematically important' financial institution. As one of the largest banks in the world, JP Morgan is similarly – if not more 'systemically important.'
As an educator, you have a special responsibility to demonstrate moral and intellectual credibility, something you have failed to do in this situation. As the president of a university, you have a responsibility to ensure that students have the best possible opportunities upon graduation. Surely you understand the connection between the unemployment crisis facing young people in America and the 2008 financial collapse. That collapse not only threatened the employment potential of millions of American students, but also risked the fiscal health of the parents and grandparents who co-signed their educational loans. That you would choose to uphold the interests of major financial institutions over students and their families is unimaginable. We certainly hope that the contributions made to Columbia by JPMorgan – sums north of $500,000 – had nothing to do with your decision.
Three years after the biggest financial crisis since the Great Depression, the country is struggling to rebuild its economy. A stable and appropriately governed financial system is a critical pre-requisite of our recovery. As the Chairman of the NY Fed, we urge you to take the obvious step of demanding Mr. Dimon's resignation.
Thank you,
Current Students, Alumni and Faculty of Columbia University
Richard Adams
Graduate Student and Alumnus
Marcellus Andrews
Professor of Economics
Columbia University
John Atlas
President of the National Housing Institute Charles H. Revson Fellow, 2004
Partha Banerjee
J-School, 2000
Hilary Beattie
Asst. Clinical Professor of Medical Psychology in Psychiatry
Carl Bettendorf
Alumnus and Adjunct Faculty
Lila Braine
Dana Burnell
Sylvia Bettendorf
Jamie Chen
CC Class of '09
Paul Colson
Jonathan Crissman
Mina Dadgar
Carolyn Douglas
Associate Professor of Psychiatry
Nnaemeka Ekwelum
Class of 2012
Tim Foreman
David Friedman
Danielle G.
Nancy Goody
Alumnae -GS of Arch & HP
Warren Green
Robert Hanning
William D. Hartung
Center for International Policy
Columbia College Class of 1978
James Hone
Bonnie Kaufman
Faculty, Medical School
Jee Kim
Columbia College, '95
Susan Lob
Adjunct Faculty and Alumni
Barbara Lundblad
Union Theological Seminary
John Markowitz
Professor of Clinical Psychiatry,
Alumnus College '76, GSAS '78, P&S '82
Rangi McNeil
School of the Arts Alumni
Sara Minard
Federick Neuhouser
Professor of Philosophy
Michael Newell
Kaveh Niazi
Jeffrey Ordower
Columbia College Class of 1991
Alexandra Pines
Class of 2016
Ai-jen Poo
National Domestic Workers Alliance
Bill Ragen
Columbia College 1980
Yuliya Rimsky
Columbia University
Alumnus Class of 2012 & SIPA student Class of 2014
Katherine Roberts
Alumna, GSAS
Eva Salzman
Jeff Schneider
Shruti Sehgal
BC Alumnus, Class of 2011
Eric J. Schoenberg
Adjunct Associate Professor
Columbia Business School
The Honorable David Segal
Former RI state representative
Anat Shenker-Osorio
Founder and Principal, ASO Communications, Columbia College '99
Kobi Skolnick
Current student of Negotiation and Conflict Resolution, Class of 2013
Jill Strauss
Denise J. Tartaglia
Stephanie Taylor
Co-Founder, Progressive Change Campaign Committee, Columbia University alumni, SOA '07
Alan Wallach
Mark Watson
James Williams
Officer Libraries
Thomas J. Yager
Associate Research Scientist, Mailman School of Public Health
Chuck Schumer Is Ruining Facebook IPO Day For One Shareholder
As you may have heard, earlier this afternoon, Facebook priced its initial public offering at $38/share, valuing co-founder Eduardo Saverin's stake at approximately $2.9 billion. Since Saverin conveniently renounced his US citizenship last week, he will avoid paying millions in capital gains taxes and hang on to an estimated $67-$100 million that would have otherwise gone to the government, news that did not sit right with Chuck Schumer. Did the Senator from New York call the guy a "piece of shit miscreant"? No. Did he send him an email that included the line, "fuck with me and you will have a huge asshole"? No. But Schumer was inspired to create draft legislation aimed at tax-dodging ex-pats like Saverin and to let the kid know he makes him sick.
Democratic Sens. Chuck Schumer (N.Y.) and Bob Casey (Pa.), who called Saverin's decision "despicable," said the Facebook co-founder stands to save $67 to $100 million in taxes by renouncing his citizenship. "Senator Casey and I have a status update for him: pay your taxes in full," Schumer said at a press conference on Capitol Hill. Their so-called "Ex-PATRIOT Act" would impose a mandatory 30 percent tax on American investments for those who renounce their citizenship and would also prohibit individuals like Saverin from re-entering the country. The law — which only applies to individuals with a net worth of over $2 million or an average income tax liability of at least $148,000 — would not apply to non-American investments by former citizens. Under the proposed legislation, the IRS would decide soon after an individual relinquishes his or her citizenship if the renouncement was motivated by tax avoidance. The individual would then have the opportunity to provide reasons for the renouncement, but there would be a "strong presumption" the move was for tax purposes. "Mr. Saverin has decided to 'defriend' the United States of America just to avoid paying his taxes," Schumer said, showing his familiarity with Facebook's lingo.
Goldman Sachs Accuser Greg Smith (Might Have) Lied About That Which He Holds Most Sacred
Earlier this week, a man named Greg Smith resigned from Goldman Sachs. Smith informed his bosses of his decision to quit around 6:40 AM local (London) time and, a few hours later, circled in the rest of the world with an Op-Ed in the New York Times, which he penned not out of a desire to violate his (former) employer in the most gruesome fashion possible in front of clients and other interested parties but because he believed it to be the right, nay the only thing to do. In the piece, Greg explain that his decision to leave the firm after 12 years of service did not come easily but that he had to do it, realizing one day during rehearsals for the recruiting video he starred in that the lines he was delivering re: Goldman being a great place to work were a lie. A bald-faced one, in fact. Goldman had changed in the years since the Greg-ster arrived, and whereas it once felt like home and the people in it family, he'd come to regard it as a den of evil, run by monsters. Monsters who called clients "muppets"; who only cared about making money; who valued "shortcuts" over "achievement." Of the latter, Greg spoke from plenty of experience. Though his personal achievements are too numerous to mention in full, they include being named a Rhodes scholar (finalist), learning to tie his shoes at the age of 22, winning third place for ping pong at the Maccabiah Games, and being named captain of the South American national table tennis team. OR WAS HE?
Greek President Would Like To Know If German FinMin Kisses His Mother With That Mouth
Greek President Karolos Papoulias slammed Germany's finance minister for recent comments about his country as […]
McKesson, Blue Cross top digital health's most trusted corporate VCs
Corporate venture capital has begun to rival "traditional" venture capital and angel investing in its importance as an investment source for healthcare industry innovation. However, unlike VCs and angels, there is a dearth of information on how the various players in the corporate venture sector operate.
Brian Dalton
Hedge Fund Manager Accused Of Insider Trading Reveals Inner 12 Year-Old Girl In Unleashing Nuclear Option On Partner In Crime
A Northern California hedge-fund manager was charged Friday with making more than $900,000 on trades […]
That's Interesting, Because Just The Other Day, Vikram Pandit Was Telling Someone That He'd Rather Hear Alec Baldwin's Opinions On Airplane Etiquette Than Mike Mayo's On How To Run A Bank
As those of you who keep up with the trials and travails of Wall Street's […]
Brad Hintz Has An Idea For Morgan Stanley
Morgan Stanley could shut down its trading businesses and the firm would be worth 40 […]
Business Professor Says He May Have To Take Drastic Measures To Protect Students From That Two-Faced Monster In Omaha
Paul Argenti is a professor at Dartmouth's Tuck School of Business, who has been teaching […]
Billionaire Hedge Fund Managers: They're Just Like Us!
They cut/piss people off on the morning commute and effectively ruin their days.
Warren Buffett Has Fighting Words For Bank CEOs' Special Lady Friends
Nothing but love for the Oracle of O but whoa there big boy! Lloyd Blankfein […]
Michael Lewis: "The World Would Be Better Off Without Goldman Sachs" And Their Kind
"I had two things going against me. I was a reporter with a camera and […]
Fox Business "Exclusively" Stonewalled By Tim Geithner
He says it's his policy not to do walk and talks but Charlie Gasparino knows […]
Anonymous Former Goldman Employee Will Pay For His Sins
Here's one: in an online survey of current and former employees, Goldman Sachs beat out […]
Bernie Madoff: Screwing The SEC, Anyone That Tickles His Fancy From Inside The Joint
CNBC reports the first bits of news from Bernie Madoff's latest prison interview. First off, […]


text:
Shilo Inn Suites Hotel - Killeen, Killeen
- Free breakfast, free WiFi in lobby, and free parking
Main amenities
- 160 smoke-free guestrooms
- Restaurant and bar/lounge
- Indoor pool
- Free airport shuttle
- Fitness center
- Spa services
- Business center
- 24-hour front desk
- Coffee/tea in the lobby
- Air conditioning
- Daily housekeeping
- Front desk safe
What's around
- Killeen Mall (1 mi / 1.7 km)
- Vive Les Arts Theatre (2 mi / 3.3 km)
- Killeen Civic and Conference Center (2.1 mi / 3.4 km)
- Stillhouse Hollow Lake (12.8 mi / 20.6 km)
The fact that we had cooking amenities was very pleasing as we had a 3-year old with us…
Absolutely loved staying in this hotel! Room was huge and bed so comfortable. Loved…
Enter dates to check prices
Hotel Info: 020 3027 9803from £63
- Junior Suite, 1 King Bed
- Junior Suite, 2 Queen Beds
- Junior Suite with King Bed
- Junior Suite with 2 Queens
Also popular with travellers from the UK
At a glance
Key facts
Hotel size
- This hotel has 160 rooms
- This hotel is arranged over 4 floors
- Check-in time starts at 4 PM
- Check-out time is Noon
Required at check in
- Credit card deposit required
- Government-issued photo ID required
Travelling with others
- Children (17 years old and younger) stay free when occupying the parent or guardian's room, using existing bedding
- Pets allowed (dogs only) *
- Restrictions apply *
- 2 per room
Extra people
- Rollaway beds available, charges may apply*
- Free WiFi and wired Internet access in public areas
- Free airport shuttle
- Free self parking
Other information
- Smoke-free property
Nearby Three Star Killeen hotels
In the hotel
- Free breakfast
- Restaurant
- Bar/lounge
- Poolside bar
- Room service (during limited hours)
- Coffee/tea in the lobby
- Indoor pool
- Fitness facilities
- Spa services on site
- Steam room
- Golfing nearby
- Sauna
- Business center
- Conference space
- Meeting rooms
- 24-hour front desk
- Laundry facilities
- Free newspapers in lobby
- Safe-deposit box at front desk
- Television in common areas
- Accessible bathroom
- In-room accessibility
In the room
- Climate control
- Air conditioning
- Coffee/tea maker
- Shower/tub combination
- Free toiletries
- Hair dryer
- Flat-screen TV
- Satellite TV channels
- Desk
- Free newspaper
- Free local calls
- Refrigerator
- Microwave
- Daily housekeeping
Top Killeen hotels
Shilo Inn Suites Hotel - Killeen, Killeen's small print
Also known as
- Shilo Inn Suites
- Shilo Inn Suites Hotel
- Shilo Inn Suites Hotel Killeen
- Shilo Inn Suites Killeen
- Killeen Shilo Inn
- Shilo Hotel Killeen
- Shilo Inn Killeen
Pet-friendly rooms can be requested by contacting the property at the number on the booking confirmation.
Mandatory fees
Pet deposit: USD 75 per stay
Optional extras
Rollaway beds are available for USD 15 per stay
Pets are allowed for an extra charge of USD 15 per accommodation, per night
We have included all charges provided to us by this hotel. However, charges can vary, for example, based on length of stay or the room you book.
Is the description of this hotel not correct? Tell us


text:
The #1 Source for All Your Sublimation Needs
Spotlight Article
Your Color is My Color
By Kevin Lumberg & TJ Kvilhaug
How the heck do I match a color with sublimation? If we heard it once, we've heard it a million times. Almost everyone has trouble matching color with sublimation... at first. But once they get the process down, it really becomes pretty easy. Most people want to look at their computer screen, and then print out the graphic and have it look exactly the same. Sorry, that is not going to happen, but we will explain to you how to easily match colors with sublimation.
Continue Reading
Read More Sublimation Articles
Creative Corner
Gallery Wrap Mural
By Rodger Vieau
If you and your customers are looking for a new medium for displaying your favorite photographs, the new canvas Gallery Wraps are just the ticket. With your digital file sized for either the 8" x 10" or 11" x 14" frame kits, (or any combination using these 4 lengths of frame pieces), you can print and press your favorite sublimatable image. The results with be art-gallery quality without the expense and time of going to a professional shop. No special tools are required for this process, just your standard sublimation printer and heat press.
For a truly eye-catching sign or display, a Gallery Wrap mural may be just the ticket. This mural was created with a combination of 6 large photos of past and present performers. Using the Power Clip feature in Corel Draw, 48 separate images were created for individual Gallery Wraps. These individual frames were then hung together to reassemble the 6 images into a single mural display. This concept can be used for a trade show display, such as ours which was used at the ARA show in Las Vegas. Or, a small combination of photos can be used in restaurants or cafe's showing some of their specialty dishes. And because these Gallery Wraps are made with the dye sublimation process versus the traditional direct print method, they can be replaced quickly and easily with your in-house sublimation equipment.
View Gallery Wraps In Our Miscellaneous Products Section
Instant Ink Rewards
Receive a 5% credit from your total sublimation ink purchase to be used towards all other items on the same order
New Product
Pre-Imaged Pet Mats
Sublimatable Lanyards
New Sublimation Product Page
Popular Product
Digital Catalog
Upcoming Training
2016 Schedule Coming Soon


text:
Numbers 16:15New International Version (NIV)
15 Then Moses became very angry and said to the Lord, "Do not accept their offering. I have not taken so much as a donkey from them, nor have I wronged any of them."
Cross references:
New International Version (NIV)
Holy Bible, New International Version®, NIV® Copyright ©1973, 1978, 1984, 2011 by Biblica, Inc.® Used by permission. All rights reserved worldwide.
Already have a redemption code? Redeem it here.
Already redeemed? Refresh the page.
This is a content preview. Buy this title to see more.


text:
Please login Or sign up for FREE with no obligations!
Views: 24021
Runtime: 29:00
Date: 5 years ago
Eating & Fucking her Ass
Yummy! I got to eat out Naughty J's sweet pussy & ass... Then fuck the *****out of her ass! If you listen you hear her ask me to stop then when I don't she says "Your not gonna stop are you." That ass is so tight made me cum so hard!
Tags: sex cock cum ass fuck fucking slut dick anal suck amateur balls tits sucking wife latina naughty creampie stroke rimjob
Top Comment
All Comments